Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Net Margin (2016 - 2026)

Gyre Therapeutics has reported Net Margin over the past 15 years, most recently at 4.63% for Q4 2025.

  • Quarterly Net Margin fell 428.0% to 4.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.31% through Dec 2025, down 712.0% year-over-year, with the annual reading at 4.31% for FY2025, 712.0% down from the prior year.
  • Net Margin was 4.63% for Q4 2025 at Gyre Therapeutics, down from 11.81% in the prior quarter.
  • Over five years, Net Margin peaked at 27.72% in Q1 2024 and troughed at 1830.73% in Q1 2022.
  • The 5-year median for Net Margin is 0.65% (2025), against an average of 408.94%.
  • Year-over-year, Net Margin plummeted -150475bps in 2021 and then soared 183973bps in 2023.
  • A 5-year view of Net Margin shows it stood at 835.53% in 2021, then skyrocketed by 96bps to 29.47% in 2022, then tumbled by -1163bps to 372.06% in 2023, then surged by 100bps to 0.36% in 2024, then crashed by -1204bps to 4.63% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Margin are 4.63% (Q4 2025), 11.81% (Q3 2025), and 1.65% (Q2 2025).